Investing.comQwen · 实盘不做把握 2/10不做原因:不是事件
北京时间·🕒 发布 20:04:39·⟳ 抓取 20:05:57 +1m18s·⚡ 决策 08-27 20:11:19 +5m22s·61.2 天前
Milestone Pharmaceuticals发布PSVT患者发作间期生活负担调查研究，将于ESC 2026大会展示
这是一项公司资助的患者生活负担描述性调查（数据来自2019年），不构成临床疗效读出、监管里程碑或商业化进展。无任何状态迁移，不改变etripamil的审批/销售前景，对股价无催化作用。微市值($1.18)、极低流动性(日成交~$834K)进一步排除交易可行性。
📄 原文Investing.com↗ 原文
Milestone presents study on PSVT impact between episodes
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook MONTREAL and CHARLOTTE, N.C. - Milestone…
不做 Milestone Pharmaceuticals（MIST.US）
患者负担调查（2019年数据）不构成任何临床/监管/商业化状态迁移，无催化剂属性；微市值$1.18、日成交不足$100万，流动性极差；我们此前对更具实质意义的MIST事件（3期试验启动）也判定不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Milestone Pharmaceuticals发布PSVT患者发作间期生活负担调查结果，数据收集于2019年，仅247人样本，由公司自行资助，目的是支持etripamil的市场推广。这不是临床疗效数据、不是监管进展、不是商业化里程碑——按生物医药经验框架，不存在任何状态迁移。MIST股价$1.18为微市值，日成交不足$100万，流动性极差。我们此前对更具实质意义的MIST事件（3期试验启动）也判定不做。本次无催化剂属性，AVOID。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
消息传播链
- Investing.com AI生成文章转发公司新闻稿，未找到公司IR原始链接；传播范围极低，无独立媒体跟进市场反应:无
主要风险
- 该研究不构成任何催化剂：无新临床数据、无监管进展、无商业化里程碑，仅为疾病认知材料
反向证据
- 做多前查反向 · 来源 web · 影响 invalidates
未找到任何独立媒体或分析师对此研究的讨论；内部KB也无相关命中；确认为低关注度非催化事件
检索:Milestone Pharmaceuticals etripamil PSVT ESC Congress 2026
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论：事件本身无催化剂属性，无需先例即可判定AVOID
方向:无可用先例
涨幅量级:无
形态:无
工具执行结果 · 成功 4 · 降级 3 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 1,260 ms
{ - search_processed_events 成功 stock_tools HTTP · 14,748 ms
{"result": "search_processed_events:agent query=`etripamil patient burden survey | milestone pharmaceuticals psvt study esc congress | mist paroxysmal supraventricular tachycardia longitudinal study`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 70.9/72 小时、11245 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息 - stock_quote 成功 stock_tools HTTP · 5,876 ms
{ - search_case_library 成功 stock_tools HTTP · 960 ms
{"result": "search_case_library「MIST.US」—— 与这些标的相关的自家决策案例(本页 2 条,该标的全历史相关记录共 2 条；ENTER 只按该标的自己的腿统计):\n◆ MIST.US：相关历史决策 2 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 2 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-08-21 UTC 不做 · 事件:Milestone Pharmaceuti - kb_search 降级 stock_tools HTTP · 6,031 ms
{ - web_search 降级 Bing RSS(Tavily 降级后备) · 1,834 ms
web_search「Milestone Pharmaceuticals MIST etripamil PSVT ESC Congress 2026 August」命中 5 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})： - web_search 降级 Bing RSS(Tavily 降级后备) · 961 ms
web_search「"Milestone Pharmaceuticals" PSVT study "European Society of Cardiology" 2026」命中 5 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})：
原文全文
展开原文 · 2,048 字
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook
MONTREAL and CHARLOTTE, N.C. - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced findings from a longitudinal study examining how paroxysmal supraventricular tachycardia affects patients between episodes, according to a press release statement.
The findings will be presented at the European Society of Cardiology Congress 2026 on August 30, 2026. The study enrolled 247 adults in the United States and United Kingdom with self-reported PSVT diagnoses and no history of catheter ablation at enrollment.
The prospective, web-based survey study tracked participants from a baseline survey in February 2019 through December 2019. Participants had a mean age of 52 years and 72% were female.
Key findings showed that approximately two in three patients adjusted their lifestyle between episodes to avoid stress, and nearly 40% reduced their activity or exercise routine. The study found 73% of patients reported daytime activity interruption between PSVT episodes.
Automobile driving and travel were the everyday activities for which avoidance between episodes was most frequently rated as bothersome or extremely bothersome, at 53% and 43% respectively. Patients reported an average anxiety level of 3.1 on a 7-point scale, with 26% reporting feeling extremely anxious at some point during the study.
Side effects of medications taken daily for PSVT were frequently reported as burdens. Fatigue and weakness were each rated as bothersome or extremely bothersome by 65% of patients. Sleep and capacity for work were the most commonly reported areas of lifestyle dissatisfaction at 30% and 22% respectively.
PSVT is a heart rhythm disorder affecting an estimated two million people in the United States, characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute.
The study was funded by Milestone Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
MONTREAL and CHARLOTTE, N.C. - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced findings from a longitudinal study examining how paroxysmal supraventricular tachycardia affects patients between episodes, according to a press release statement.
The findings will be presented at the European Society of Cardiology Congress 2026 on August 30, 2026. The study enrolled 247 adults in the United States and United Kingdom with self-reported PSVT diagnoses and no history of catheter ablation at enrollment.
The prospective, web-based survey study tracked participants from a baseline survey in February 2019 through December 2019. Participants had a mean age of 52 years and 72% were female.
Key findings showed that approximately two in three patients adjusted their lifestyle between episodes to avoid stress, and nearly 40% reduced their activity or exercise routine. The study found 73% of patients reported daytime activity interruption between PSVT episodes.
Automobile driving and travel were the everyday activities for which avoidance between episodes was most frequently rated as bothersome or extremely bothersome, at 53% and 43% respectively. Patients reported an average anxiety level of 3.1 on a 7-point scale, with 26% reporting feeling extremely anxious at some point during the study.
Side effects of medications taken daily for PSVT were frequently reported as burdens. Fatigue and weakness were each rated as bothersome or extremely bothersome by 65% of patients. Sleep and capacity for work were the most commonly reported areas of lifestyle dissatisfaction at 30% and 22% respectively.
PSVT is a heart rhythm disorder affecting an estimated two million people in the United States, characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute.
The study was funded by Milestone Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。